等待开盘 12-20 09:30:00 美东时间
+0.852
+1.60%
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. announced the sale of approximately $2.3 million in convertible promissory notes and warrants, as part of a $5 million offering. The notes mature in July 2026, bear 6% interest, and convert into common stock at 80% of the average closing price up to $0.40. Warrants for 200% of conversion shares will follow. Proceeds will fund research, including a Phase 1b/2 trial, and general corporate use.
06-13 12:00
Indaptus Therapeutics begins a new trial arm to study the safety, dosing, and anti-tumor activity of combining Decoy20 with Beigene's PD-1 inhibitor tislelizumab in patients with advanced solid tumors that have not responded to prior checkpoint inhibitors or are typically unresponsive.
06-02 12:00
https://verticalmag.com/press-releases/cae-secures-u-s-navy-foreign-military-sales-contract-to-support-mh-60r-training-for-india/ CAE announced that CAE Defense & Security USA has been awarded a contract by the United States Navy under a U.S. Foreign Military Sales (FMS) program to provide two train...
2024-09-04 21:59